Catabasis Pharmaceuticals (NASDAQ:CATB) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.07, Yahoo Finance reports.
Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) opened at $2.09 on Friday. The company has a market capitalization of $44.32, a PE ratio of -1.39 and a beta of 0.80. Catabasis Pharmaceuticals has a twelve month low of $1.09 and a twelve month high of $3.78.
Several research firms have recently weighed in on CATB. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday, December 15th. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Thursday, November 16th. Finally, Citigroup upgraded Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Monday, November 20th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $4.82.
ILLEGAL ACTIVITY NOTICE: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://ledgergazette.com/2018/03/16/catabasis-pharmaceuticals-catb-releases-quarterly-earnings-results-beats-estimates-by-0-07-eps.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.